CTMX - CytomX Therapeutics Inc logo

CytomX Therapeutics Inc

CTMX

CytomX Therapeutics develops targeted biologics for oncology, focusing on its Probody platform to create antibody-drug conjugates and T-cell engagers for treating solid tumors. Its pipeline includes innovative treatments for various cancers through strategic partnerships.

⚕️ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago →$187today

Score Overview

1 Year
Score
Net Growth-358.62%
Net TrendShrank
Net Income Consistency—
Rev Growth-75.98%
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.1
Net Growth1.23%
Net TrendNever
Net Income Consistency—
Rev Growth-73.69%
Rev Trend40%
Revenue Consistency—
10 Years
Score
Net Growth-35.23%
Net Trend25%
Net Income Consistency
Rev Growth21.66%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-125.17%
Net Trend22%
Net Income Consistency
Rev Growth137.32%
Rev Trend55%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where CytomX Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CTMX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 2.40—
1 Year2025-10-21
$ 3.62-33.61%
5 Years2021-10-21
$ 5.11-53.03%
10 Years2016-10-21
$ 12.85-81.32%
All Time2015-10-08
$ 12.90-81.40%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 18M-$ 79M$ 330M
2025$ 76M-$ 17M$ 137M
2024$ 138M$ 31M$ 100M
2023$ 101M$ 174M
2022$ 53M-$ 97M$ 193M
2021$ 69M-$ 80M$ 305M
2020$ 68M-$ 64M$ 316M
2019$ 57M-$ 102M$ 296M
2018$ 59M-$ 84M$ 436M
2017$ 71M-$ 43M$ 374M
2016$ 15M-$ 58M$ 181M
IPO2015$ 7M-$ 35M$ 186M
CTMX - CytomX Therapeutics Inc logo

CytomX Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 68M to $ 76M and net income went from -$ 64M to -$ 17M. Revenue increased in 2 of those 5 years; net income in 0.

Across CytomX Therapeutics Inc's full reported history, from 2015 to 2025, revenue grew from $ 7M to $ 76M and net income went from -$ 35M to -$ 17M. Revenue increased in 55% of the years measured; net income in 22%.

CytomX Therapeutics Inc currently holds a 5-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.

Membership

Explore CTMX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies